Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.46 |
| ▸ | THRA | P10827 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138167 | 0.81 | PPARA (0.34) | THRBTHRA | |
| SCHEMBL3138235 | 0.76 | THRA (0.42) | THRBTHRA | |
| SCHEMBL3979678 | 0.69 | THRA (0.56) | THRBTHRAMAPTLDHAALDH1A1 | |
| SCHEMBL3146203 | 0.68 | THRA (0.58) | THRBTHRAKCNH2NPC1RAB9A | |
| SCHEMBL3140784 | 0.64 | THRA (0.55) | THRBTHRAMAPTNPC1RAB9A | |
| SCHEMBL3137511 | 0.64 | THRA (0.52) | THRBTHRAMAPT | |
| Eprotirome SCHEMBL759034 | 0.63 | THRA (1.00) | THRBTHRA | |
| Eprotirome SCHEMBL29357083 | 0.63 | THRA (1.00) | THRBTHRA | |
| SCHEMBL3133764 | 0.63 | THRA (0.54) | THRBTHRA | |
| SCHEMBL3136227 | 0.61 | HDAC1 (0.38) | THRBTHRAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1899309-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007003419-A1 | HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTOR | KARO BIO AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004271-A1 | HETEROCYCLIC COMPOUNDS AS AGANIST FOR THE THYROID RECEPTOR | TSHR, GHSR, TRHR | THRB 6/4885THRA 4/4885SMN1; SMN2 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.